HLA matching in mismatched unrelated donor allogeneic hematopoietic cell transplantation
| Reference . | Consensus guidelines . | |||
|---|---|---|---|---|
| Dehn et al20 (2019) | 1. 7/8 match at ARD level for HLA-A, B, C, DRB1 2. Younger donor age 3. Match or permissive HLA-DPB1 TCE 4. Minimize mismatches at HLA-DRB3/4/5 and DQB1 5. Avoid DSA targets including DQA1 and DPA1 | |||
| New research published, since release of guidelines | ||||
| Study | Population | Trial/study design | Comparison | Results |
| Petersdorf et al33 (2020) | N = 33 982 total cohort with N = 1457 HLA-B mismatched, first alloHCT for multiple diseases, CNI-based GVHD prophylaxis | Observational study | Exon 1 B leader match vs mismatch in 9/10 MMUD | B leader match associated with decreased acute GVHD, no association between match status and survival |
| Shaw et al7 (2021) | N = 80 7/8-4/8 MMUD alloHCT for hematologic malignancies, ptCy-based GVHD prophylaxis with bone marrow grafts | Prospective trial | 7/8 matched vs <7/8 matched | No differences in any outcomes |
| Reference . | Consensus guidelines . | |||
|---|---|---|---|---|
| Dehn et al20 (2019) | 1. 7/8 match at ARD level for HLA-A, B, C, DRB1 2. Younger donor age 3. Match or permissive HLA-DPB1 TCE 4. Minimize mismatches at HLA-DRB3/4/5 and DQB1 5. Avoid DSA targets including DQA1 and DPA1 | |||
| New research published, since release of guidelines | ||||
| Study | Population | Trial/study design | Comparison | Results |
| Petersdorf et al33 (2020) | N = 33 982 total cohort with N = 1457 HLA-B mismatched, first alloHCT for multiple diseases, CNI-based GVHD prophylaxis | Observational study | Exon 1 B leader match vs mismatch in 9/10 MMUD | B leader match associated with decreased acute GVHD, no association between match status and survival |
| Shaw et al7 (2021) | N = 80 7/8-4/8 MMUD alloHCT for hematologic malignancies, ptCy-based GVHD prophylaxis with bone marrow grafts | Prospective trial | 7/8 matched vs <7/8 matched | No differences in any outcomes |
CNI, calcineurin inhibitor; 7/8, single high-resolution mismatch at HLA-A, B, C, and DRB1; 9/10, single high-resolution mismatch at HLA-A, B, C, DRB1, and DQB1.